157 related articles for article (PubMed ID: 28833323)
1. Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects.
Prado Y; Zambrano T; Salazar LA
J Clin Pharm Ther; 2018 Feb; 43(1):87-91. PubMed ID: 28833323
[TBL] [Abstract][Full Text] [Related]
2. Gender-Specific Association Between ABCC2 -24C>T SNP and Reduction in Triglycerides in Chilean Patients Treated With Atorvastatin.
Prado Y; Arencibia A; Zambrano T; Salazar LA
Basic Clin Pharmacol Toxicol; 2018 May; 122(5):517-522. PubMed ID: 29178257
[TBL] [Abstract][Full Text] [Related]
3. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
[TBL] [Abstract][Full Text] [Related]
4. HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals.
Cuevas A; Fernández C; Ferrada L; Zambrano T; Rosales A; Saavedra N; Salazar LA
Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):292-7. PubMed ID: 26408409
[TBL] [Abstract][Full Text] [Related]
5. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.
Kadam P; Ashavaid TF; Ponde CK; Rajani RM
J Clin Pharm Ther; 2016 Jun; 41(3):329-33. PubMed ID: 26932749
[TBL] [Abstract][Full Text] [Related]
6. High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants.
Tsuchiya K; Hayashida T; Hamada A; Oki S; Oka S; Gatanaga H
Pharmacogenet Genomics; 2017 Nov; 27(11):416-419. PubMed ID: 28858994
[TBL] [Abstract][Full Text] [Related]
7. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Tandia M; Mhiri A; Paule B; Saffroy R; Cailliez V; Noé G; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2017 Apr; 79(4):759-766. PubMed ID: 28289864
[TBL] [Abstract][Full Text] [Related]
8. Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia.
Li M; Kong XY; Wang SM
Cancer Chemother Pharmacol; 2023 Jan; 91(1):77-87. PubMed ID: 36463535
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
[TBL] [Abstract][Full Text] [Related]
10. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
Cerda A; Genvigir FD; Arazi SS; Hirata MH; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
Clin Chim Acta; 2010 May; 411(9-10):631-7. PubMed ID: 20064494
[TBL] [Abstract][Full Text] [Related]
11. [Polymorphism of ABCB1 and ABCG2 genes encoding drug transporters and their investigation by pyrosequencing].
Dribnokhodova OP; Mironov KO; Dunaeva EA; Shipulin GA
Eksp Klin Farmakol; 2012; 75(10):29-36. PubMed ID: 23240156
[TBL] [Abstract][Full Text] [Related]
12. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
[TBL] [Abstract][Full Text] [Related]
13. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
Rosales A; Alvear M; Cuevas A; Saavedra N; Zambrano T; Salazar LA
Clin Chim Acta; 2012 Feb; 413(3-4):495-501. PubMed ID: 22120734
[TBL] [Abstract][Full Text] [Related]
14. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
15. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphisms in ABCG5 and ABCG8 genes in Chilean subjects with polygenic hypercholesterolemia and controls.
Caamaño JM; Pacheco A; Lanas F; Salazar LA
Clin Chem Lab Med; 2008; 46(11):1581-5. PubMed ID: 19012522
[TBL] [Abstract][Full Text] [Related]
17. Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments.
To KK; Hu M; Tomlinson B
Pharmacogenomics; 2014 Jun; 15(8):1091-104. PubMed ID: 25084202
[TBL] [Abstract][Full Text] [Related]
18. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
[TBL] [Abstract][Full Text] [Related]
19. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin.
Jiang XY; Zhang Q; Chen P; Li SY; Zhang NN; Chen XD; Wang GC; Wang HB; Zhuang MQ; Lu M
J Clin Pharm Ther; 2012 Dec; 37(6):719-23. PubMed ID: 22882727
[TBL] [Abstract][Full Text] [Related]
20. Effect of ABCB1 genotype on pre- and post-cardiac transplantation plasma lipid concentrations.
Taegtmeyer AB; Breen JB; Smith J; Rogers P; Kullak-Ublick GA; Yacoub MH; Banner NR; Barton PJ
J Cardiovasc Transl Res; 2011 Jun; 4(3):304-12. PubMed ID: 21445698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
